Context Therapeutics Inc 2025年度报告

For the fiscal year ended December31, 2025 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-40654 CONTEXT THERAPEUTICS INC. Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes No☒ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes No☒ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding12months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.Yes☒No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes☒No Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of“large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. Largeacceleratedfiler☐AcceleratedfilerNon-accelerated filer☒SmallerreportingcompanyEmerging growthcompany If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financialaccounting standards provided pursuant to Section 13(a) of the Exchange Act. Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financialreporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C 7262(b)) by the registered public accounting firm that prepared or issued its audit report. If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect thecorrection of an error to previously issued financial statements. Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of theregistrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes☐No☒ As of June 30, 2025 (the last business day of the registrant's most recently completed second fiscal quarter), the aggregate market value ofthe registrant's common stock held by non-affiliates was approximately $57.9million based on the last reported sale price of the registrant'scommon stock on The Nasdaq Stock Market on June 30, 2025. As of March19, 2026, the registrant had 91,879,177 shares of common stock, $0.001 par value per share, outstanding. DOCUMENTS INCORPORATED BY REFERENCE Portions of the registrant’s definitive Proxy Statement for its 2026 Annual Meeting of Stockholders to be filed with the Securities andExchange Commission pursuant to Regulation 14A not later than 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K are incorporated by reference in Part III, Items 10-14 of this Annual Report on Form 10-K. TABLE OF CONTENTS Unless the context otherwise requires, all references in this Form 10-K to "Context," the "Company," "we," "us," and "our" refer to ContextTherapeutics Inc. and its subsidiaries._________________________ Trademark Notice This Form 10-K contains references to our trademarks and to trademarks belonging to other entities. Context Therapeutics® is a registeredtrademark of Context in the United States. All other trademarks, trade names and service marks appearing in this Form 10-K are the property oftheir respective owners. We do not intend our use or display of other companies' trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other RISK FACTOR SUMMARY The risk factors summarized below could materially harm our business, operating results and/or financial condition, impair our futureprospects and/or cause the price of our common stock to decline. For more information, see “Item 1A. Risk Factors” in this Annual Report onForm 10-K for the year ended December31, 2025. Material risks that may affect our business, operating results and financial condition include,but are not necessarily limited to, the following: Risks Related to Our Business and Industry• We have never been profitable and may never achieve or maintain profitability.•We will need to raise additional funding, which may not be available